XTX602

XTX602 is an investigational, preclinical dual-masked, multi-specific T-cell engager (TCE) being developed by Xilio Therapeutics for the treatment of claudin 18.2 (CLDN18.2)-expressing gastrointestinal cancers, including gastric, esophageal, and pancreatic cancers. The molecule is designed to target CLDN18.2 on tumor cells and engage T cells via CD3, with both binding domains masked to minimize systemic and gastrointestinal toxicities in non-tumor tissues. Additionally, XTX602 incorporates a built-in CD2 co-stimulatory domain to enhance T-cell activation, expansion, and durability of response, particularly in tumors with low CLDN18.2 expression.